Base de dados : MEDLINE
Pesquisa : I01.409.418.750.600.650.496.465 [Categoria DeCS]
Referências encontradas : 84 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 9 ir para página                      

  1 / 84 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28314660
[Au] Autor:Karlawish J; Jack CR; Rocca WA; Snyder HM; Carrillo MC
[Ad] Endereço:Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
[Ti] Título:Alzheimer's disease: The next frontier-Special Report 2017.
[So] Source:Alzheimers Dement;13(4):374-380, 2017 Apr.
[Is] ISSN:1552-5279
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:In the history of medicine, one means to progress is when we make the decision that our assumptions and definitions of disease are no longer consistent with the scientific evidence, and no longer serve our health care needs. The arc of scientific progress is now requiring a change in how we diagnose Alzheimer's disease. Both the National Institute on Aging-Alzheimer's Association (NIA-AA) 2011 workgroup and the International Work Group (IWG) have proposed guidelines that use detectable measures of biological changes in the brain, commonly known as biological markers, or biomarkers, as part of the diagnosis. This Special Report examines how the development and validation of Alzheimer's disease biomarkers-including those detectable in the blood or cerebral spinal fluid, or through neuroimaging-is a top research priority. This has the potential to markedly change how we diagnose Alzheimer's disease and, as a result, how we count the number of people with this disease. As research advances a biomarker-based method for diagnosis and treatment at the earliest stages of Alzheimer's disease, we envision a future in which Alzheimer's disease is placed in the same category as other chronic diseases, such as cardiovascular disease or diabetes, which can be readily identified with biomarkers and treated before irrevocable disability occurs.
[Mh] Termos MeSH primário: Doença de Alzheimer/diagnóstico
[Mh] Termos MeSH secundário: Doença de Alzheimer/epidemiologia
Doença de Alzheimer/metabolismo
Doença de Alzheimer/terapia
Biomarcadores/metabolismo
Seres Humanos
Internacionalidade
National Institute on Aging (U.S.)
Guias de Prática Clínica como Assunto
Sociedades Médicas
Estados Unidos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171006
[Lr] Data última revisão:
171006
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170319
[St] Status:MEDLINE


  2 / 84 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28304301
[Au] Autor:Alosco ML; Duskin J; Besser LM; Martin B; Chaisson CE; Gunstad J; Kowall NW; McKee AC; Stern RA; Tripodis Y
[Ad] Endereço:Boston University Alzheimer's Disease and CTE Center, Boston University School of Medicine, Boston, MA, USA.
[Ti] Título:Modeling the Relationships Among Late-Life Body Mass Index, Cerebrovascular Disease, and Alzheimer's Disease Neuropathology in an Autopsy Sample of 1,421 Subjects from the National Alzheimer's Coordinating Center Data Set.
[So] Source:J Alzheimers Dis;57(3):953-968, 2017.
[Is] ISSN:1875-8908
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:The relationship between late-life body mass index (BMI) and Alzheimer's disease (AD) is poorly understood due to the lack of research in samples with autopsy-confirmed AD neuropathology (ADNP). The role of cerebrovascular disease (CVD) in the interplay between late-life BMI and ADNP is unclear. We conducted a retrospective longitudinal investigation and used joint modeling of linear mixed effects to investigate causal relationships among repeated antemortem BMI measurements, CVD (quantified neuropathologically), and ADNP in an autopsy sample of subjects across the AD clinical continuum. The sample included 1,421 subjects from the National Alzheimer's Coordinating Center's Uniform Data Set and Neuropathology Data Set with diagnoses of normal cognition (NC; n = 234), mild cognitive impairment (MCI; n = 201), or AD dementia (n = 986). ADNP was defined as moderate to frequent neuritic plaques and Braak stageIII-VI. Ischemic Injury Scale (IIS) operationalized CVD. Joint modeling examined relationships among BMI, IIS, and ADNP in the overall sample and stratified by initial visit Clinical Dementia Rating score. Subject-specific random intercept for BMI was the predictor for ADNP due to minimal BMI change (p = 0.3028). Analyses controlling for demographic variables and APOE É›4 showed lower late-life BMI predicted increased odds of ADNP in the overall sample (p < 0.001), and in subjects with CDR of 0 (p = 0.0021) and 0.5 (p = 0.0012), but not ≥1.0 (p = 0.2012). Although higher IIS predicted greater odds of ADNP (p < 0.0001), BMI did not predict IIS (p = 0.2814). The current findings confirm lower late-life BMI confers increased odds for ADNP. Lower late-life BMI may be a preclinical indicator of underlying ADNP.
[Mh] Termos MeSH primário: Doença de Alzheimer/patologia
Índice de Massa Corporal
Transtornos Cerebrovasculares/patologia
Neuropatologia
[Mh] Termos MeSH secundário: Idoso
Idoso de 80 Anos ou mais
Autopsia
Conjuntos de Dados como Assunto
Feminino
Seres Humanos
Masculino
National Institute on Aging (U.S.)/estatística & dados numéricos
Testes Neuropsicológicos
Estudos Retrospectivos
Estados Unidos/epidemiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170825
[Lr] Data última revisão:
170825
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170318
[St] Status:MEDLINE
[do] DOI:10.3233/JAD-161205


  3 / 84 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28191798
[Au] Autor:Blanco-Cantó ME; Monge-Argilés JA; Pérez-Cejuela C; Badía C; Gabaldón L; Muñoz-Ruíz C; Sánchez-Payá J; Gasparini-Berenguer R; Leiva-Santana C
[Ad] Endereço:1 Department of Neurology, General University Hospital of Alicante, Alicante, Spain.
[Ti] Título:Diagnostic Validity Comparison Between Criteria Based on CSF Alzheimer's Disease Biomarkers.
[So] Source:Am J Alzheimers Dis Other Demen;32(2):101-107, 2017 Mar.
[Is] ISSN:1938-2731
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:AIM: To compare the diagnostic validity of NIA-AA criteria, for AD CSF biomarkers, with our own new criteria. MATERIALS AND METHODS: Between 2008 and 2011, 170 patients with Mild Cognitive Impairment (MCI) were included. CSF levels of Aß1-42, T-tau, P-tau181, and ratios of T-tau/Aß1-42 and P-tau181/Aß1-42 were analyzed. In our criteria, we considered 3 or more abnormal variables indicative of a high likelihood of MCI due to AD. RESULTS: After a clinical follow-up of 4.5 ± 1.2 years, 44 patients remained stable, 95 developed AD, 15 other forms of dementia, 7 died and 9 received other diagnoses. Using the NIA-AA criteria and our own criteria, the diagnostic validity of the CSF biomarkers was 58% versus 85%, specificity 84% versus 72%, PPV 82% versus 79% and NPV 61% versus 79%. CONCLUSION: The inclusion of the ratios in diagnostic criteria increases sensitivity and NPV for the diagnosis of MCI due to AD.
[Mh] Termos MeSH primário: Doença de Alzheimer/líquido cefalorraquidiano
Peptídeos beta-Amiloides/líquido cefalorraquidiano
Biomarcadores/líquido cefalorraquidiano
Disfunção Cognitiva/líquido cefalorraquidiano
Fragmentos de Peptídeos/líquido cefalorraquidiano
Proteínas tau/líquido cefalorraquidiano
[Mh] Termos MeSH secundário: Idoso
Idoso de 80 Anos ou mais
Feminino
Seguimentos
Seres Humanos
Masculino
Meia-Idade
National Institute on Aging (U.S.)/normas
Guias de Prática Clínica como Assunto/normas
Reprodutibilidade dos Testes
Sensibilidade e Especificidade
Estados Unidos
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Amyloid beta-Peptides); 0 (Biomarkers); 0 (Peptide Fragments); 0 (amyloid beta-protein (1-42)); 0 (tau Proteins)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171004
[Lr] Data última revisão:
171004
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170214
[St] Status:MEDLINE
[do] DOI:10.1177/1533317516688298


  4 / 84 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28062571
[Au] Autor:Flanagan ME; Marshall DA; Shofer JB; Montine KS; Nelson PT; Montine TJ; Keene CD
[Ad] Endereço:Department of Pathology, Stanford University, Stanford, CA, USA.
[Ti] Título:Performance of a Condensed Protocol That Reduces Effort and Cost of NIA-AA Guidelines for Neuropathologic Assessment of Alzheimer Disease.
[So] Source:J Neuropathol Exp Neurol;76(1):39-43, 2017 01 01.
[Is] ISSN:1554-6578
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Concerns regarding resource expenditures have been expressed about the 2012 NIA-AA Sponsored Guidelines for neuropathologic assessment of Alzheimer disease (AD) and related dementias. Here, we investigated a cost-reducing Condensed Protocol and its effectiveness in maintaining the diagnostic performance of Guidelines in assessing AD, Lewy body disease (LBD), microvascular brain injury, hippocampal sclerosis (HS), and congophilic amyloid angiopathy (CAA). The Condensed Protocol consolidates the same 20 regions into 5 tissue cassettes at ∼75% lower cost. A 28 autopsy brain-retrospective cohort was selected for varying levels of neuropathologic features in the Guidelines (Original Protocol), as well as an 18 consecutive autopsy brain prospective cohort. Three neuropathologists at 2 sites performed blinded evaluations of these cases. Lesion specificity was similar between Original and Condensed Protocols. Sensitivities for AD neuropathologic change, LBD, HS, and CAA were not substantially impacted by the Condensed Protocol, whereas sensitivity for microvascular lesions (MVLs) was decreased. Specificity for CAA was decreased using the Condensed Protocol when compared with the Original Protocol. Our results show that the Condensed Protocol is a viable alternative to the NIA-AA guidelines for AD neuropathologic change, LBD, and HS, but not MVLs or CAA, and may be a practical alternative in some practice settings.
[Mh] Termos MeSH primário: Doença de Alzheimer/economia
Doença de Alzheimer/patologia
Redução de Custos/normas
National Institute on Aging (U.S.)/economia
National Institute on Aging (U.S.)/normas
Guias de Prática Clínica como Assunto/normas
[Mh] Termos MeSH secundário: Encéfalo/patologia
Estudos de Coortes
Redução de Custos/métodos
Seres Humanos
Estudos Prospectivos
Estudos Retrospectivos
Método Simples-Cego
Estados Unidos
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170717
[Lr] Data última revisão:
170717
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170108
[St] Status:MEDLINE
[do] DOI:10.1093/jnen/nlw104


  5 / 84 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27858974
[Au] Autor:Fung CH; Vitiello MV; Alessi CA; Kuchel GA; AGS/NIA Sleep Conference Planning Committee and Faculty
[Ad] Endereço:Geriatric Research, Education and Clinical Center, Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California.
[Ti] Título:Report and Research Agenda of the American Geriatrics Society and National Institute on Aging Bedside-to-Bench Conference on Sleep, Circadian Rhythms, and Aging: New Avenues for Improving Brain Health, Physical Health, and Functioning.
[So] Source:J Am Geriatr Soc;64(12):e238-e247, 2016 Dec.
[Is] ISSN:1532-5415
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The American Geriatrics Society, with support from the National Institute on Aging and other funders, held its eighth Bedside-to-Bench research conference, entitled "Sleep, Circadian Rhythms, and Aging: New Avenues for Improving Brain Health, Physical Health and Functioning," October 4 to 6, 2015, in Bethesda, Maryland. Part of a conference series addressing three common geriatric syndromes-delirium, sleep and circadian rhythm (SCR) disturbance, and voiding dysfunction-the series highlighted relationships and pertinent clinical and pathophysiological commonalities between these three geriatric syndromes. The conference provided a forum for discussing current sleep, circadian rhythm, and aging research; identifying gaps in knowledge; and developing a research agenda to inform future investigative efforts. The conference also promoted networking among developing researchers, leaders in the field of SCR and aging, and National Institutes of Health program personnel.
[Mh] Termos MeSH primário: Envelhecimento
Pesquisa Biomédica/tendências
Ritmo Circadiano
Geriatria
Transtornos do Sono-Vigília/fisiopatologia
Transtornos do Sono-Vigília/terapia
[Mh] Termos MeSH secundário: Idoso
Seres Humanos
National Institute on Aging (U.S.)
Sociedades Médicas
Estados Unidos
[Pt] Tipo de publicação:CONGRESSES
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170717
[Lr] Data última revisão:
170717
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161119
[St] Status:MEDLINE
[do] DOI:10.1111/jgs.14493


  6 / 84 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26888304
[Au] Autor:Ringman JM; Monsell S; Ng DW; Zhou Y; Nguyen A; Coppola G; Van Berlo V; Mendez MF; Tung S; Weintraub S; Mesulam MM; Bigio EH; Gitelman DR; Fisher-Hubbard AO; Albin RL; Vinters HV
[Ad] Endereço:From the Mary S. Easton Center for Alzheimer's Disease Research, University of California, Los Angeles, Department of Neurology, Los Angeles, California (JMR, DWN, YZ, AN, GC, MFM, ST, HVV); Memory and Aging Center, Keck School of Medicine of University of Southern California, Los Angeles, Californi
[Ti] Título:Neuropathology of Autosomal Dominant Alzheimer Disease in the National Alzheimer Coordinating Center Database.
[So] Source:J Neuropathol Exp Neurol;75(3):284-90, 2016 Mar.
[Is] ISSN:1554-6578
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Alzheimer disease (AD) represents a genetically heterogeneous entity. To elucidate neuropathologic features of autosomal dominant AD ([ADAD] due to PSEN1, APP, or PSEN2 mutations), we compared hallmark AD pathologic findings in 60 cases of ADAD and 120 cases of sporadic AD matched for sex, race, ethnicity, and disease duration. Greater degrees of neuritic plaque and neurofibrillary tangle formation and cerebral amyloid angiopathy (CAA) were found in ADAD (p values < 0.01). Moderate to severe CAA was more prevalent in ADAD (63.3% vs. 39.2%, p = 0.003), and persons with PSEN1 mutations beyond codon 200 had higher average Braak scores and severity and prevalence of CAA than those with mutations before codon 200. Lewy body pathology was less extensive in ADAD but was present in 27.1% of cases. We also describe a novel pathogenic PSEN1 mutation (P267A). The finding of more severe neurofibrillary pathology and CAA in ADAD, particularly in carriers of PSEN1 mutations beyond codon 200, warrants consideration when designing trials to treat or prevent ADAD. The finding of Lewy body pathology in a substantial minority of ADAD cases supports the assertion that development of Lewy bodies may be in part driven by abnormal ß-amyloid protein precursor processing.
[Mh] Termos MeSH primário: Doença de Alzheimer/patologia
Neuropatologia
Presenilina-1/genética
[Mh] Termos MeSH secundário: Idoso
Idoso de 80 Anos ou mais
Doença de Alzheimer/genética
Precursor de Proteína beta-Amiloide/genética
Apolipoproteínas E/genética
Bases de Dados Factuais/estatística & dados numéricos
Feminino
Seres Humanos
Masculino
Meia-Idade
Mutação/genética
National Institute on Aging (U.S.)/estatística & dados numéricos
Presenilina-2/genética
Estados Unidos/epidemiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL
[Nm] Nome de substância:
0 (Amyloid beta-Protein Precursor); 0 (Apolipoproteins E); 0 (PSEN1 protein, human); 0 (PSEN2 protein, human); 0 (Presenilin-1); 0 (Presenilin-2)
[Em] Mês de entrada:1607
[Cu] Atualização por classe:170510
[Lr] Data última revisão:
170510
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160219
[St] Status:MEDLINE
[do] DOI:10.1093/jnen/nlv028


  7 / 84 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26327235
[Au] Autor:Montine TJ; Monsell SE; Beach TG; Bigio EH; Bu Y; Cairns NJ; Frosch M; Henriksen J; Kofler J; Kukull WA; Lee EB; Nelson PT; Schantz AM; Schneider JA; Sonnen JA; Trojanowski JQ; Vinters HV; Zhou XH; Hyman BT
[Ad] Endereço:Department of Pathology, University of Washington, Seattle, WA, USA. Electronic address: tmontine@u.washington.edu.
[Ti] Título:Multisite assessment of NIA-AA guidelines for the neuropathologic evaluation of Alzheimer's disease.
[So] Source:Alzheimers Dement;12(2):164-169, 2016 Feb.
[Is] ISSN:1552-5279
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: Neuropathologic assessment is the current "gold standard" for evaluating the Alzheimer's disease (AD), but there is no consensus on the methods used. METHODS: Fifteen unstained slides (8 brain regions) from each of the 14 cases were prepared and distributed to 10 different National Institute on Aging AD Centers for application of usual staining and evaluation following recently revised guidelines for AD neuropathologic change. RESULTS: Current practice used in the AD Centers Program achieved robustly excellent agreement for the severity score for AD neuropathologic change (average weighted κ = .88, 95% confidence interval: 0.77-0.95) and good-to-excellent agreement for the three supporting scores. Some improvement was observed with consensus evaluation but not with central staining of slides. Evaluation of glass slides and digitally prepared whole-slide images was comparable. DISCUSSION: AD neuropathologic evaluation as performed across AD Centers yields data that have high agreement with potential modifications for modest improvements.
[Mh] Termos MeSH primário: Doença de Alzheimer/patologia
Encéfalo/patologia
Neuropatologia/normas
Guias de Prática Clínica como Assunto
[Mh] Termos MeSH secundário: Doença de Alzheimer/diagnóstico
Seres Humanos
National Institute on Aging (U.S.)
Neuropatologia/métodos
Estados Unidos
Instituições Filantrópicas de Saúde
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY; RESEARCH SUPPORT, N.I.H., EXTRAMURAL
[Em] Mês de entrada:1609
[Cu] Atualização por classe:170729
[Lr] Data última revisão:
170729
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150902
[St] Status:MEDLINE


  8 / 84 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26253588
[Au] Autor:Alexopoulos P; Roesler J; Thierjung N; Werle L; Buck D; Yakushev I; Gleixner L; Kagerbauer S; Ortner M; Grimmer T; Kübler H; Martin J; Laskaris N; Kurz A; Perneczky R
[Ad] Endereço:Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar, Technische Universität München, Munich, Germany. panos.alexopoulos@lrz.tum.de.
[Ti] Título:Mapping CSF biomarker profiles onto NIA-AA guidelines for Alzheimer's disease.
[So] Source:Eur Arch Psychiatry Clin Neurosci;266(7):587-97, 2016 Oct.
[Is] ISSN:1433-8491
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:The National Institute on Aging-Alzheimer's Association (NIA-AA) guidelines for Alzheimer's disease (AD) propose the categorization of individuals according to their biomarker constellation. Though the NIA-AA criteria for preclinical AD and AD dementia have already been applied in conjunction with imaging AD biomarkers, the application of the criteria using comprehensive cerebrospinal fluid (CSF) biomarker information has not been thoroughly studied yet. The study included a monocentric cohort with healthy (N = 41) and disease (N = 22) controls and patients with AD dementia (N = 119), and a multicentric sample with healthy controls (N = 116) and patients with AD dementia (N = 102). The CSF biomarkers ß-amyloid 1-42, total tau, and phosphorylated tau at threonine 181 were measured with commercially available assays. Biomarker values were trichotomized into positive for AD, negative, or borderline. In controls the presence of normal CSF profiles varied between 13.6 and 25.4 % across the studied groups, while up to 8.6 % of them had abnormal CSF biomarkers. In 40.3-52.9 % of patients with AD dementia, a typical CSF profile for AD was detected. Approximately 40 % of the potential biomarker constellations are not considered in the NIA-AA guidelines, and more than 40 % of participants could not be classified into the NIA-AA categories with distinct biomarker constellations. Here, a refined scheme covering all potential biomarker constellations is proposed. These results enrich the discussion on the NIA-AA guidelines and point to a discordance between clinical symptomatology and CSF biomarkers even in patients with full-blown AD dementia, who are supposed to have a clearly positive for AD neurochemical profile.
[Mh] Termos MeSH primário: Doença de Alzheimer/líquido cefalorraquidiano
Peptídeos beta-Amiloides/líquido cefalorraquidiano
Biomarcadores/líquido cefalorraquidiano
National Institute on Aging (U.S.)/normas
Fragmentos de Peptídeos/líquido cefalorraquidiano
Sociedades Médicas/normas
Proteínas tau/líquido cefalorraquidiano
[Mh] Termos MeSH secundário: Idoso
Idoso de 80 Anos ou mais
Doença de Alzheimer/classificação
Feminino
Seres Humanos
Masculino
Meia-Idade
Estados Unidos
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY
[Nm] Nome de substância:
0 (Amyloid beta-Peptides); 0 (Biomarkers); 0 (Peptide Fragments); 0 (amyloid beta-protein (1-42)); 0 (tau Proteins)
[Em] Mês de entrada:1702
[Cu] Atualização por classe:170928
[Lr] Data última revisão:
170928
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150809
[St] Status:MEDLINE
[do] DOI:10.1007/s00406-015-0628-7


  9 / 84 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:24662500
[Au] Autor:Garrett MD; Valle R
[Ad] Endereço:School of Social Work, San Diego State University, CA, USA mariusgarrett@yahoo.com.
[Ti] Título:A methodological critique of the National Institute of Aging and Alzheimer's Association Guidelines for Alzheimer's disease, dementia, and mild cognitive impairments.
[So] Source:Dementia (London);15(2):239-54, 2016 Mar.
[Is] ISSN:1741-2684
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:In 2011, the U.S. National Institute on Aging published guidelines for clinical diagnostics for Alzheimer's disease dementia. These guidelines define a continuum with three stages-an early, pre-clinical stage with no symptoms, followed by mild cognitive impairment, and a final stage of Alzheimer's disease dementia. This methodological critique examines the validity of this continuum. No studies exist showing the progression of these biomarkers to Alzheimer's disease. There is also a lack of empirical evidence showing how biomarkers determine mild cognitive impairment, which has multiple etiologies. The guidelines fail to explain anomalies where there are biomarkers but no expression of Alzheimer's disease.
[Mh] Termos MeSH primário: Doença de Alzheimer/diagnóstico
Biomarcadores
Disfunção Cognitiva/diagnóstico
Estudos de Avaliação como Assunto
National Institute on Aging (U.S.)
Guias de Prática Clínica como Assunto/normas
[Mh] Termos MeSH secundário: Progressão da Doença
Seres Humanos
Neuropatologia
Estados Unidos
[Pt] Tipo de publicação:JOURNAL ARTICLE; VALIDATION STUDIES
[Nm] Nome de substância:
0 (Biomarkers)
[Em] Mês de entrada:1610
[Cu] Atualização por classe:170103
[Lr] Data última revisão:
170103
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:140326
[St] Status:MEDLINE
[do] DOI:10.1177/1471301214525166


  10 / 84 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:26675362
[Au] Autor:Hill CV; Pérez-Stable EJ; Anderson NA; Bernard MA
[Ad] Endereço:1.National Institute on Aging of the National Institute of Health.
[Ti] Título:The National Institute on Aging Health Disparities Research Framework.
[So] Source:Ethn Dis;25(3):245-54, 2015 Aug 07.
[Is] ISSN:1049-510X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: Development of a new framework for the National Institute on Aging (NIA) to assess progress and opportunities toward stimulating and supporting rigorous research to address health disparities. DESIGN: Portfolio review of NIA's health disparities research portfolio to evaluate NIA's progress in addressing priority health disparities areas. RESULTS: The NIA Health Disparities Research Framework highlights important factors for health disparities research related to aging, provides an organizing structure for tracking progress, stimulates opportunities to better delineate causal pathways and broadens the scope for malleable targets for intervention, aiding in our efforts to address health disparities in the aging population. CONCLUSIONS: The promise of health disparities research depends largely on scientific rigor that builds on past findings and aggressively pursues new approaches. The NIA Health Disparities Framework provides a landscape for stimulating interdisciplinary approaches, evaluating research productivity and identifying opportunities for innovative health disparities research related to aging.
[Mh] Termos MeSH primário: Envelhecimento
Pesquisa sobre Serviços de Saúde/métodos
Serviços de Saúde para Idosos
Disparidades em Assistência à Saúde
National Institute on Aging (U.S.)/estatística & dados numéricos
[Mh] Termos MeSH secundário: Idoso
Seres Humanos
Estados Unidos
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; REVIEW
[Em] Mês de entrada:1602
[Cu] Atualização por classe:170220
[Lr] Data última revisão:
170220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:151218
[St] Status:MEDLINE
[do] DOI:10.18865/ed.25.3.245



página 1 de 9 ir para página                      
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde